These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 28976791)

  • 1. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
    Fuchs CS; Niedzwiecki D; Mamon HJ; Tepper JE; Ye X; Swanson RS; Enzinger PC; Haller DG; Dragovich T; Alberts SR; Bjarnason GA; Willett CG; Gunderson LL; Goldberg RM; Venook AP; Ilson D; O'Reilly E; Ciombor K; Berg DJ; Meyerhardt J; Mayer RJ
    J Clin Oncol; 2017 Nov; 35(32):3671-3677. PubMed ID: 28976791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
    Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
    Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
    Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
    BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
    Ustaalioglu BBO; Bilici A; Tilki M; Surmelioglu A; Erkol B; Figen M; Uyar S
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S736-S741. PubMed ID: 30249896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.
    Leong T; Smithers BM; Haustermans K; Michael M; Gebski V; Miller D; Zalcberg J; Boussioutas A; Findlay M; O'Connell RL; Verghis J; Willis D; Kron T; Crain M; Murray WK; Lordick F; Swallow C; Darling G; Simes J; Wong R
    Ann Surg Oncol; 2017 Aug; 24(8):2252-2258. PubMed ID: 28337660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Enzinger PC; Burtness BA; Niedzwiecki D; Ye X; Douglas K; Ilson DH; Villaflor VM; Cohen SJ; Mayer RJ; Venook A; Benson AB; Goldberg RM
    J Clin Oncol; 2016 Aug; 34(23):2736-42. PubMed ID: 27382098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study.
    Kaytan Saglam E; Yucel S; Balik E; Saglam S; Asoglu O; Yamaner S; Bugra D; Oral EN; Kizir A; Kapran Y; Sakar B; Akyuz A; Gulluoglu M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):361-7. PubMed ID: 25189794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
    Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
    Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
    Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A;
    Ann Oncol; 2014 Jul; 25(7):1373-1378. PubMed ID: 24728035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
    McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
    J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, epirubicin and cisplatin (modified ECF) as adjuvant chemotherapy in resected gastric adenocarcinoma.
    Unek IT; Unek T; Oztop I; Akman T; Atilla K; Ellidokuz H; Bora S; Sarioglu S; Yilmaz U
    Chemotherapy; 2012; 58(3):233-40. PubMed ID: 22832016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
    Smalley SR; Benedetti JK; Williamson SK; Robertson JM; Estes NC; Maher T; Fisher B; Rich TA; Martenson JA; Kugler JW; Benson AB; Haller DG; Mayer RJ; Atkins JN; Cripps C; Pedersen J; Periman PO; Tanaka MS; Leichman CG; Macdonald JS
    J Clin Oncol; 2006 Aug; 24(22):3542-7. PubMed ID: 16877719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Concurrent Chemoradiotherapy (CRT) plus Docetaxel-Cisplatin-Fluorouracil (DCF) versus CRT plus Fluorouracil-Folinic Acid (FUFA) in Stage III Gastric Cancer.
    Alkan A; Mızrak D; Yaşar A; Karcı E; Köksoy EB; Ürün M; Özyurt N; Kuştaş AA; Kütük T; Ürün Y; Şenler FÇ; Akyürek S; Utkan G; Demirkazık A; Gökçe ŞÇ; Akbulut H
    J Cancer Res Ther; 2024 Apr; 20(3):913-917. PubMed ID: 39023597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
    Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
    Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.